Key result
Pregnancy in DCM with LVEF <40% carries serious risks and ACE inhibitors pose fetal toxicity.
Why the study?
Dilated cardiomyopathy is rare and can lead to serious complications during pregnancy due to increased cardiac output and plasma volume.
What are the maternal and fetal risks of dilated cardiomyopathy and ACE inhibitor exposure during pregnancy?
Case Report (n=1)
What are the maternal and fetal risks of dilated cardiomyopathy and ACE inhibitor exposure during pregnancy?
Answers are grounded in this paper and cite their sources.
Pregnancy in patients with dilated cardiomyopathy carries significant maternal risks, and ACE inhibitor exposure is associated with fetotoxicity, necessitating a multidisciplinary approach.
Dilated cardiomyopathy (DCM) is a rare disease that can lead to serious cardiac complications, especially during pregnancy.In this study, a case of DCM in an advanced pregnancy with no known history of the disease resulting in spontaneous delivery is presented.Pregnancy in patients with DCM may have adverse outcomes because of increased cardiac output and plasma volume.This case demonstrates that pregnancy carries serious risks, particularly in patients with an ejection fraction <40%.The fetotoxic effects of angiotensin-converting enzyme inhibitors use during pregnancy are emphasized, and the importance of a multidisciplinary approach is highlighted.
No takes yet. Share an insight, caveat, or question.
Aydın et al. (2024) conducted a case report in Dilated cardiomyopathy in pregnancy (n=1). Angiotensin-converting enzyme inhibitors was evaluated. Pregnancy in a patient with dilated cardiomyopathy and an ejection fraction <40% carries serious risks, and ACE inhibitor use during pregnancy has fetotoxic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: